Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, has been awarded the 2026 Biotech Breakthrough Award for Cancer Immunology Solution of the Year for its investigational therapy ENV-105 (carotuximab), according to a company announcement distributed via BioMedWire. The award recognizes the company’s approach to overcoming treatment resistance in metastatic prostate cancer and non-small cell lung cancer by developing therapies designed to restore and extend the effectiveness of existing cancer treatments.
ENV-105 is an investigational neutralizing antibody being evaluated in combination with standard-of-care therapies. The recognition follows recently reported positive interim efficacy data from Kairos Pharma’s ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The interim analysis demonstrated a statistically significant difference in progression-free survival between patients receiving the combination therapy and those receiving apalutamide alone. The full press release is available at https://ibn.fm/GnUxn.
The news matters for patients with hard-to-treat cancers and for the broader oncology drug development field. Drug resistance remains a major obstacle in cancer care, often limiting how long existing therapies can control disease. If ENV-105 succeeds in later trials, it could offer a new way to extend the benefit of standard treatments, potentially improving outcomes for patients with metastatic prostate cancer and non-small cell lung cancer. For investors, the award and interim data may signal growing external validation of the company’s platform, though the therapy remains investigational and further clinical testing is required.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution.
